The FDA-approved cyanocobalamin injection is a 1000 mcg/mL aqueous solution in a multi-dose vial, and the dose schedule (daily for a week, then weekly, then monthly) was calibrated for the average pernicious anemia patient. That product does not account for the patient who reacts to the benzyl alcohol preservative in the manufactured vial, the patient whose prescriber wants to deliver 1 to 5 mg as an IV push and needs a concentration that does not exist commercially, the patient who cannot tolerate injections at all, or the patient whose protocol calls for B12 combined with folate, methylfolate, or other B vitamins in one syringe.
That is the gap a compounding pharmacy fills. The molecule is the same cyanocobalamin the FDA reviewed. What changes is the concentration (5 or 10 mg/mL for IV-push protocols outside the commercial 1 mg/mL strength), the preservative profile (benzyl-alcohol-free and chlorobutanol-free formulations for documented sensitivity), the route (custom-strength sublingual troches for patients who refuse injections), and the formula (multi-vitamin injectables blending B12 with folate, methylfolate, B6, or hydroxocobalamin on a prescriber's individualized order). None of these are available off the shelf, which is the entire point. Routine substitution of compounded B12 for the cheap manufactured generic is not what 503A is for, and RonanRx does not do it.
This is what pharmacy looked like before mass manufacturing. A prescriber wrote the order for a specific patient, and a pharmacist prepared it on the bench. Compounded cyanocobalamin is that older arrangement, kept honest by state inspection and the named-patient prescription on file.
In brief
Cyanocobalamin Explained
Cyanocobalamin is one form of vitamin B12, the cobalt-containing vitamin your body uses to make red blood cells, build the myelin sheath around nerves, and recycle the amino acid homocysteine. Most people get B12 from animal foods; the body cannot make it.
The classic deficiency syndrome is pernicious anemia, in which the stomach stops producing intrinsic factor (the protein that lets the small intestine absorb B12). Without B12, red blood cells become large and fragile, and nerves can slowly fail, causing numbness, balance problems, and memory changes. Cyanocobalamin injection (1000 micrograms intramuscularly) corrects the deficiency 21. High-dose oral cyanocobalamin (1000, 2000 micrograms daily) is also effective, even in pernicious anemia, because a small fraction of B12 is absorbed by passive diffusion at high doses 510.
Cyanocobalamin injection is an FDA-approved generic product that has been used clinically for over half a century. Compounded cyanocobalamin from a 503A pharmacy is appropriate only when the manufactured product cannot meet a specific clinical need, for example, a custom concentration for an IV-push, a preservative-free formulation for a patient with benzyl-alcohol sensitivity, or a B-complex or methylation-cocktail injectable that combines B12 with other vitamins 16.
Cyanocobalamin, a synthetic vitamin B12 vitamer in which the upper axial ligand on the central cobalt is a cyano group; converted intracellularly to the bioactive coenzymes methylcobalamin and 5'-deoxyadenosylcobalamin
FDA-approved branded and generic forms
Cyanocobalamin injection (1000 mcg/mL, IM or deep SC; FDA-approved generic, decades of clinical use); Nascobal nasal spray (500 mcg/0.1 mL intranasal); multiple OTC oral tablets and solutions
Route
Intramuscular, deep subcutaneous, oral, sublingual, and intranasal
Evidence posture
Decades of clinical use; randomized trials and a Cochrane systematic review establish oral and parenteral cyanocobalamin as effective for correcting vitamin B12 deficiency
FDA-approval status
Manufactured cyanocobalamin injection and Nascobal intranasal spray are FDA-approved. Compounded cyanocobalamin preparations are not FDA-approved.
Compounded under
503A, patient-specific prescription, justified when commercial cyanocobalamin products cannot meet a documented clinical need (custom strengths, allergen-free formulations, IV-push concentrations, mixed-vitamin injectables)
Honest framing
FDA-approved cyanocobalamin injection is a generic, inexpensive, and widely available product. Compounding is appropriate only when individualization a manufactured product cannot provide is clinically required, not as a routine substitution.
Prescription review
Patient-Specific Prescription Only
Cyanocobalamin on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Cyanocobalamin?
Cyanocobalamin is a synthetic form of vitamin B12. Vitamin B12 (cobalamin) is a corrinoid: a tetrapyrrole macrocycle similar to heme but with a central cobalt ion. The corrin ring carries a lower axial ligand, 5,6-dimethylbenzimidazole linked via a ribose-phosphate-aminopropanol arm, and an upper axial ligand that varies between vitamers. In cyanocobalamin the upper ligand is a cyano group; in methylcobalamin it is a methyl group; in adenosylcobalamin it is a 5'-deoxyadenosyl group; in hydroxocobalamin it is a hydroxyl group 1425.
Cyanocobalamin is the most chemically stable cobalamin vitamer and is the form historically used in pharmaceuticals, food fortification, and most over-the-counter supplements. After absorption, cyanocobalamin is intracellularly converted by the MMACHC enzyme, which removes the cyano group, to a common cob(II)alamin intermediate that is then channeled into the two active coenzyme forms: methylcobalamin (cytosolic, cofactor for methionine synthase) and 5'-deoxyadenosylcobalamin (mitochondrial, cofactor for methylmalonyl-CoA mutase) 2514.
The FDA-approved manufactured cyanocobalamin products include parenteral cyanocobalamin injection (typically 1000 mcg/mL aqueous solution, intramuscular or deep subcutaneous), Nascobal nasal spray (500 mcg/0.1 mL intranasal), and multiple oral tablets and solutions available over the counter 2728. The manufactured injection is a generic product that has been used clinically for more than half a century at a low unit cost.
How it works
How Cyanocobalamin Works
Class
Vitamin B12 (cyano form)
First studied
1950s
Common forms
Subcutaneous or intramuscular injection
Compounding category
503A, patient-specific prescription
Vitamin B12 is an essential cofactor for two human enzymes. Methionine synthase, a cytosolic enzyme that uses methylcobalamin, transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine and tetrahydrofolate. Methylmalonyl-CoA mutase, a mitochondrial enzyme that uses 5'-deoxyadenosylcobalamin, isomerizes methylmalonyl-CoA (derived from odd-chain fatty acid and branched-chain amino acid catabolism) to succinyl-CoA, which then enters the citric acid cycle 1621.
When B12 is deficient, methionine synthase activity falls, homocysteine accumulates, and 5-methyltetrahydrofolate becomes trapped (the 'methyl folate trap'), producing functional folate deficiency in marrow precursors and the megaloblastic anemia phenotype. In parallel, methylmalonyl-CoA mutase activity falls, methylmalonic acid accumulates, and abnormal odd-chain fatty acids are incorporated into myelin lipids, contributing to subacute combined degeneration of the spinal cord and peripheral neuropathy 16123.
Cyanocobalamin itself is biologically inert until intracellular processing removes the cyano group; the MMACHC-mediated decyanation generates a reactive cob(II)alamin that is methylated to methylcobalamin or adenosylated to 5'-deoxyadenosylcobalamin 2514. Methylmalonic acid and total plasma homocysteine therefore serve as functional markers of intracellular B12 status, both fall within days of effective repletion regardless of vitamer used 63.
Research history
Cyanocobalamin Research History
The discovery of vitamin B12 emerged from the work on pernicious anemia in the 1920s. George Minot and William Murphy showed in 1926 that feeding large quantities of raw liver produced clinical and hematological remission in patients with pernicious anemia. William Castle in 1929 demonstrated that the gastric juice of healthy donors, but not of patients with pernicious anemia, contained an 'intrinsic factor' that worked together with an 'extrinsic factor' in food to produce the antianemic effect. The active substance was isolated in crystalline form in 1948 (Rickes, Smith, and Folkers at Merck; Lester Smith at Glaxo), and its molecular structure was determined by Dorothy Hodgkin and colleagues by X-ray crystallography in 1956 (a feat that contributed to her 1964 Nobel Prize in Chemistry). The Minot-Murphy work earned the 1934 Nobel Prize in Physiology or Medicine 2116.
Clinical use of parenteral cyanocobalamin became standard within years of its isolation; the 1000 mcg IM repletion-then-maintenance schedule that remains in widespread use today originated in the 1950s. The Berlin group's mid-century work and subsequent trials established that high-dose oral cobalamin (1000, 2000 mcg daily) is absorbed by intrinsic-factor-independent passive diffusion at sufficient quantity to produce hematological remission even in pernicious anemia. Kuzminski et al. randomized 38 patients with newly diagnosed cobalamin deficiency to oral cyanocobalamin 2000 mcg daily or intramuscular cyanocobalamin 1000 mcg on the standard induction-then-maintenance schedule and found equivalent serum cobalamin, methylmalonic acid, and homocysteine normalization 5. Bolaman et al. extended this comparison in patients with megaloblastic anemia 7. The Vidal-Alaball 2005 Cochrane systematic review pooled the available randomized evidence, and the updated Wang 2018 Cochrane review reaffirmed the conclusion: oral cyanocobalamin is equivalent to parenteral cyanocobalamin for correction of B12 deficiency at appropriate doses 1022. Practice guidelines from the British Committee for Standards in Haematology codified these findings in 2014 18.
Parallel research extended the deficiency syndrome and its biochemical diagnosis. Lindenbaum and colleagues showed in 1988 that neuropsychiatric manifestations of cobalamin deficiency can occur in the absence of anemia or macrocytosis, undermining the historical reliance on the complete blood count as a screen 1. Stabler, Allen, Savage, and Lindenbaum demonstrated that serum methylmalonic acid and total plasma homocysteine are markedly more sensitive than serum cobalamin for biochemical diagnosis 326. Epidemiological work in elderly adults established food-cobalamin malabsorption, failure to release B12 from food protein in patients with atrophic gastritis and reduced gastric acid, as the dominant cause of B12 deficiency after age 65 9423, and dedicated studies established the prevalence of B12 deficiency in vegetarians and vegans 17. The DPPOS cohort showed a dose-dependent association between long-term metformin use and biochemical B12 deficiency in adults with type 2 diabetes 20. The 2010 VITACOG trial demonstrated that homocysteine-lowering with B vitamins slowed the rate of brain atrophy in adults with mild cognitive impairment and elevated homocysteine 15, although subsequent pooled analyses did not consistently translate to a clinically meaningful slowing of cognitive decline.
Timeline
Cyanocobalamin Timeline
1926Minot and Murphy show that raw liver feeding produces remission in pernicious anemia 21
1929William Castle demonstrates the gastric 'intrinsic factor' required for absorption of an 'extrinsic factor' in food 21
1948Vitamin B12 isolated in crystalline form (Rickes, Smith, Folkers at Merck; Lester Smith at Glaxo) 21
1956Dorothy Hodgkin solves the X-ray crystal structure of vitamin B12, the corrin ring with central cobalt 21
1988Lindenbaum et al 1. (NEJM) demonstrate that neuropsychiatric manifestations of cobalamin deficiency occur in the absence of anemia or macrocytosis
1990Stabler et al 2. (Blood) review the clinical spectrum and biochemical diagnosis of cobalamin deficiency, establishing methylmalonic acid and homocysteine as functional markers
1994Savage et al 3. (Am J Med) demonstrate the diagnostic sensitivity of serum methylmalonic acid and total homocysteine for cobalamin and folate deficiency
1998Kuzminski et al 5. (Blood) randomize 38 patients to oral 2000 mcg vs IM 1000 mcg cyanocobalamin, equivalent biochemical correction; mechanistic basis for high-dose oral therapy
1999Snow (Arch Intern Med) primary-care guide to laboratory diagnosis of vitamin B12 and folate deficiency 6
2003Bolaman et al 7. (Clin Ther) prospective randomized comparison of oral vs IM cobalamin in megaloblastic anemia
2004Andrès (CMAJ) and Stabler (Annu Rev Nutr) review B12 deficiency in the elderly and as a worldwide problem; food-cobalamin malabsorption framed as dominant geriatric mechanism 98
2005Vidal-Alaball et al 10. publish the first Cochrane systematic review of oral vs intramuscular cyanocobalamin
2006Eussen et al 1112. (AJCN) randomized trial of oral cyanocobalamin in elderly adults with mild B12 deficiency; Reynolds (Lancet Neurol) reviews B12 and the nervous system
2010Smith et al 15. (PLoS ONE), VITACOG randomized trial: homocysteine-lowering with B vitamins (folic acid, B12, B6) slows brain atrophy in mild cognitive impairment
2013Stabler (NEJM) Clinical Practice review of vitamin B12 deficiency 16
2014Pawlak (Eur J Clin Nutr) reviews B12 deficiency prevalence among vegetarians; Devalia et al 171819. publish BCSH guideline for diagnosis and treatment of cobalamin and folate disorders; Hunt (BMJ) primary-care review
2016Aroda et al 20. (JCEM), DPPOS analysis demonstrates dose-dependent association of long-term metformin use with biochemical B12 deficiency in adults with type 2 diabetes
2017Green et al 21. publish the Nature Reviews Disease Primers monograph on vitamin B12 deficiency
2018Wang et al 22. updated Cochrane systematic review confirms equivalence of oral vs IM cyanocobalamin for B12 deficiency
2019Wolffenbuttel et al 23. (Mayo Clin Proc IQO) review 'the many faces of cobalamin deficiency'
2020Andrès (QJM) state-of-the-art review of oral and nasal vitamin B12 therapy in the elderly 24
2022Hannibal (Vitam Horm) reviews intracellular cobalamin processing by MMACHC, the molecular step that decyanates cyanocobalamin 25
2024Lacombe et al 26. (AJCN) prospective cohort confirms effectiveness of oral cyanocobalamin in patients with pernicious anemia
Natural role
Biological Role of Cyanocobalamin
Vitamin B12 is one of eight B vitamins and one of two single-carbon-metabolism cofactors (the other is folate). The methionine cycle, the folate cycle, and the methylmalonyl-CoA mutase reaction together situate B12 at the intersection of nucleotide synthesis, methylation, and odd-chain fatty acid catabolism. Methionine produced by methionine synthase is the precursor of S-adenosylmethionine (SAM), the universal methyl donor for hundreds of methyltransferase reactions, including DNA methylation, neurotransmitter synthesis, and myelin basic protein methylation 1216.
Humans cannot synthesize cobalamin; it is produced exclusively by certain bacteria and archaea. Dietary sources are animal foods (meat, fish, eggs, dairy) and, to a smaller extent, B12-fortified foods. Plant foods do not contain meaningful amounts of bioavailable cobalamin; algae and fermented foods contain mostly inactive corrinoid analogs 1317. Recommended dietary intake in adults is 2.4 mcg/day; daily losses (biliary excretion and shedding of cobalamin-rich cells) are well below 1% of body stores per day, so deficiency manifests slowly, typically years after onset of malabsorption or dietary inadequacy 21.
Clinical contexts studied
Clinical Contexts for Cyanocobalamin
Treatment of vitamin B12 deficiency (megaloblastic anemia and neurological deficiency) fda approved
FDA-approved indication for manufactured cyanocobalamin injection and Nascobal intranasal spray.
Cyanocobalamin injection is FDA-approved for the treatment of pernicious anemia and other causes of vitamin B12 deficiency including dietary inadequacy, malabsorption syndromes, and inadequate utilization 51022. The standard induction-then-maintenance schedule is 1000 mcg IM daily for one week, weekly for one month, then monthly for life in patients with permanent malabsorption 27. Randomized trials and Cochrane systematic reviews demonstrate that oral cyanocobalamin 1000, 2000 mcg daily achieves equivalent biochemical and hematological correction in patients with pernicious anemia and other malabsorption phenotypes 726. Nascobal intranasal spray (500 mcg once weekly) is FDA-approved for maintenance after initial parenteral repletion in patients in hematological remission 28.
Pernicious anemia (autoimmune intrinsic factor deficiency) fda approved
FDA-approved indication for parenteral cyanocobalamin; high-dose oral established by randomized trials.
Pernicious anemia is the autoimmune destruction of gastric parietal cells producing intrinsic factor deficiency and B12 malabsorption 2226. Anti-intrinsic-factor antibodies are highly specific; anti-parietal-cell antibodies are more sensitive but less specific. Parenteral cyanocobalamin produces complete hematological correction within weeks and neurological improvement over weeks to months 182728. High-dose oral cyanocobalamin (1000, 2000 mcg daily) is an alternative for patients in whom adherence can be assured 5710.
Branded product: Cyanocobalamin injection (generic) and Nascobal nasal spray
Food-cobalamin malabsorption (elderly atrophic gastritis) well studied
Well-studied dominant geriatric mechanism of B12 deficiency; FDA-approved cyanocobalamin products are routinely used.
After age 65, the dominant cause of B12 deficiency is food-cobalamin malabsorption: atrophic gastritis with hypochlorhydria reduces the gastric acid and pepsin needed to release B12 from food protein, but crystalline (free) cyanocobalamin in tablets or injections is absorbed normally because it does not require this proteolytic release step 423. Oral cyanocobalamin therapy is therefore highly effective in this population 24. The prevalence of subclinical B12 deficiency in community-dwelling older adults is approximately 5, 20% depending on the diagnostic threshold and biomarker used 16219.
Vitamin B12 deficiency in vegans and vegetarians well studied
Well-studied dietary etiology; cyanocobalamin supplementation is the standard intervention.
Plant foods contain no biologically meaningful vitamin B12; cobalamin found in algae and fermented foods is predominantly inactive corrinoid analog 13. Pawlak et al. systematically reviewed cobalamin status across vegetarian and vegan populations and found prevalences of deficiency reaching 62% in pregnant vegetarian women and 86% in elderly vegans depending on biomarker definitions 17. Cyanocobalamin oral supplementation (typically 1000 mcg daily or 2000 mcg weekly) corrects and prevents deficiency in this population 21.
Metformin-induced vitamin B12 deficiency well studied
Well-studied; B12 supplementation is recommended in patients on long-term metformin who develop biochemical deficiency.
The Diabetes Prevention Program Outcomes Study (DPPOS) demonstrated a dose-dependent association between cumulative metformin exposure and biochemical B12 deficiency in adults with type 2 diabetes, risk approximately doubled in long-term metformin users compared with placebo 201621. The proposed mechanism is interference with calcium-dependent ileal uptake of the intrinsic factor-B12 complex. Periodic biochemical screening (serum B12, with reflex to methylmalonic acid or homocysteine when borderline) and oral cyanocobalamin supplementation are reasonable in patients on long-term metformin.
Neuropsychiatric manifestations of cobalamin deficiency well studied
Well-studied syndrome; cyanocobalamin replacement is the standard of care.
Subacute combined degeneration of the spinal cord (posterior column and lateral corticospinal tract involvement), peripheral neuropathy, cognitive decline, depression, and psychotic presentations have all been described as B12 deficiency syndromes. Lindenbaum et al. demonstrated that 28% of 141 patients with neuropsychiatric manifestations of cobalamin deficiency had no anemia and no macrocytosis at presentation 11621. Reynolds reviewed the spectrum of neurological involvement and the rationale for prompt replacement 12. Neurological recovery is variable and incomplete when treatment is delayed; the urgency to recognize, biochemically confirm with methylmalonic acid and homocysteine, and replete is driven by this risk of permanent deficit.
Homocysteine-lowering for cognitive decline prevention well studied
Studied in randomized trials with mixed and modest results; do not extrapolate to non-deficient adults.
The VITACOG randomized trial 15 demonstrated that homocysteine-lowering with high-dose B vitamins (folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg daily) slowed the rate of brain atrophy on MRI in older adults with mild cognitive impairment and elevated homocysteine, the strongest available evidence of a biologically plausible MRI signal 15. Pooled trial data on cognitive outcomes have been less consistent, and the practical inference is to diagnose and replete true B12 deficiency rather than to administer B vitamins as a dementia prophylactic in B12-replete adults 1621.
Off-label use
Off-Label Uses of Cyanocobalamin
'Energy' or fatigue indications in patients with normal serum B12 emerging
Common indication for prescribing in practice; not supported by randomized evidence in B12-replete adults.
Subjective improvements in energy, mood, or wellbeing are widely reported after B12 injection in patients without biochemical deficiency. Randomized placebo-controlled evidence does not support a specific B12 effect in adults with serum B12 in the normal range; the appropriate clinical approach is to confirm or exclude deficiency biochemically (serum B12 with reflex methylmalonic acid and homocysteine in borderline cases) before treating. When deficiency is confirmed, fatigue and cognitive symptoms commonly improve with replacement 1621.
FDA-approved use
FDA-Approved Uses of Cyanocobalamin
Brand
Indication
Year
Route
Cyanocobalamin injection (generic)
Treatment of vitamin B12 deficiency, including pernicious anemia, dietary deficiency, malabsorption syndromes, and inadequate utilization; vitamin B12 absorption (Schilling) test
Decades, multiple generic NDAs / ANDAs
Intramuscular or deep subcutaneous injection
Nascobal (cyanocobalamin nasal spray)
Maintenance of normal hematologic status in patients with pernicious anemia who are in hematologic remission following intramuscular vitamin B12 therapy; supplemental B12 for patients with B12 deficiency from dietary deficiencies, malabsorption diseases, or inadequate utilization
2005
Intranasal
Cyanocobalamin has multiple FDA-approved manufactured products. Parenteral cyanocobalamin injection (1000 mcg/mL aqueous solution, intramuscular or deep subcutaneous) is a generic that has been used clinically for over half a century, labeled for treatment of vitamin B12 deficiency from pernicious anemia, malabsorption, dietary inadequacy, or increased requirements, and historically for the Schilling absorption test 27. Nascobal nasal spray (500 mcg/0.1 mL, one spray weekly) is FDA-approved for maintenance therapy after parenteral repletion in patients with pernicious anemia in hematological remission 28. Multiple over-the-counter oral cyanocobalamin tablets and solutions are widely available.
Compounded cyanocobalamin preparations are not FDA-approved. The manufactured generic cyanocobalamin injection is widely available and inexpensive; compounded versions must rest on a documented patient-specific clinical reason that the manufactured product cannot meet, consistent with FDA's section 503A 'essentially a copy' guidance 29.
Compounded use
Compounded Cyanocobalamin (503A)
Cyanocobalamin is one of the more honestly framed compounding scenarios on the RonanRx formulary. The FDA-approved generic cyanocobalamin injection (1000 mcg/mL) is a low-cost, widely available drug 27. The legitimate role of 503A compounding is therefore narrow and specific: compounded cyanocobalamin should be dispensed only when a documented patient-specific clinical need cannot be met by the manufactured product 2930.
Documented patient-specific needs that justify a compounded cyanocobalamin preparation include: (1) custom concentration, for example, 5 mg/mL or 10 mg/mL for IV-push administration in protocols that deliver 1, 5 mg per dose, which is not a commercially available manufactured strength; (2) excipient sensitivity, preservative-free formulations for patients with documented benzyl alcohol or chlorobutanol hypersensitivity, since most multi-dose manufactured vials contain one of these preservatives; (3) custom-strength sublingual troches or oral preparations for patients who cannot tolerate injections and who require strengths not commercially available; (4) multi-vitamin injectables, B12 prepared as a component of a B-complex or methylation-cocktail injectable (with folate or methylfolate, hydroxocobalamin, B6, and other vitamins) on a prescriber's individualized formula. None of these use cases is met by the commercially available 1000 mcg/mL cyanocobalamin injection 27.
Routine substitution of compounded cyanocobalamin for the manufactured generic, for example, the dispensing of a 1000 mcg/mL aqueous compounded injection identical in composition to the commercial product, is not appropriate under FDA's section 503A essentially-a-copy guidance and is not a service RonanRx provides 29. The honest framing is that the manufactured cyanocobalamin injection works, is inexpensive, and is the appropriate product for the great majority of patients; compounding earns its place only where individualization the manufactured product cannot provide is clinically required 27.
Compounded sterile cyanocobalamin preparations are prepared per USP General Chapter <797>; nonsterile preparative steps (when applicable) follow USP General Chapter <795> 3132. Stability, sterility, endotoxin testing, container closure, and beyond-use dating are documented per the pharmacy's quality-management system and per the relevant USP standards.
1000 mcg/mL (1 mg/mL) aqueous solution, single- or multi-dose vials; multi-dose vials typically contain benzyl alcohol as preservative
FDA-approved generic. Standard parenteral product for treatment of pernicious anemia and other causes of B12 deficiency. Routine repletion-then-maintenance schedule is 1000 mcg IM daily for one week, then weekly for one month, then monthly for life in permanent malabsorption.27
Nascobal intranasal spray (reference product)
500 mcg per 0.1 mL spray; one spray weekly
FDA-approved intranasal cyanocobalamin for maintenance of B12 status after parenteral repletion in pernicious anemia.28
Oral cyanocobalamin (OTC)
Typical tablets 100, 5000 mcg
Widely available over the counter. High-dose oral cyanocobalamin (1000, 2000 mcg daily) is equivalent to parenteral cyanocobalamin for correction of B12 deficiency in randomized trials and Cochrane meta-analysis.51022
Custom, typical compounded strengths include 5 mg/mL and 10 mg/mL for IV-push or high-dose IM protocols not commercially available
Prepared under USP <797> on patient-specific prescriptions when the manufactured 1000 mcg/mL product cannot meet a documented clinical need (e.g., 1, 5 mg IV-push dosing, preservative-free formulation, B-complex injectable).31
Compounded sublingual troche or high-strength oral preparation
Custom, patient-specific strengths and excipient profiles
Prepared under USP <795> for patients who require an oral or sublingual cyanocobalamin preparation at a strength or in an excipient profile not commercially available.32
Routes used in published literature: intramuscular, subcutaneous, intravenous, oral, sublingual, intranasal.
Dosing
Cyanocobalamin Dosing
Route
Population
Range
Duration
Study type
Intramuscular
Adults with vitamin B12 deficiency from pernicious anemia or other malabsorption (FDA-labeled regimen)
1000 mcg IM daily for one week; then 1000 mcg IM weekly for one month; then 1000 mcg IM monthly for life (or as long as the underlying cause persists). Alternative repletion schedules in the literature include 1000 mcg IM every other day for one to two weeks, then less frequently.
Adults receiving high-dose B12 protocols in clinical settings where commercial 1000 mcg/mL strength is impractical
1, 5 mg per dose; frequency per prescriber protocol
Per prescriber protocol
Pharmacy compounding practice; no dedicated phase-3 program, supported by general pharmacology of cyanocobalamin2731
Subcutaneous (deep SC, manufactured or compounded)
Adults intolerant of IM injection or on patient-preference SC route per prescriber
1000 mcg SC, on the same induction-then-maintenance schedule as the IM route
Indefinite while underlying cause persists
FDA-approved alternative route on the cyanocobalamin injection label27
Sublingual (compounded)
Adults requiring oral therapy who prefer or require a sublingual route
1000, 2000 mcg sublingually daily (mirroring oral regimen)
Indefinite while underlying cause persists
Pharmacy compounding practice; sublingual absorption likely similar to high-dose oral passive diffusion5
Doctor-prescribed. The classic intramuscular cyanocobalamin schedule (1000 mcg daily for one week, weekly for one month, then monthly) was empirically chosen in the 1950s and has not been displaced by a single more efficient parenteral regimen. High-dose oral cyanocobalamin (1000, 2000 mcg daily) is an equally effective alternative for many patients including those with pernicious anemia, provided adherence can be reasonably assured 2757. The choice between routes is typically practical: severe presentations with neurological involvement are often treated parenterally for at least the first few weeks before considering a switch to oral; food-cobalamin malabsorption in older adults often responds well to oral therapy from the outset 102226.
Biochemical correction is monitored by serum B12, methylmalonic acid, and homocysteine (the last two normalize within days of effective repletion); hematological correction is monitored by complete blood count and reticulocyte response (a reticulocytosis peaks at approximately one week) 2718. Neurological improvement is slower, variable, and incomplete when treatment is delayed, the urgency to recognize and treat is driven by this risk of permanent deficit 16121.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Cyanocobalamin Safety
Safety overview
Cyanocobalamin has an exceptionally favorable safety profile across more than half a century of clinical use. The most common adverse effects of parenteral administration are mild injection-site reactions (pain, pruritus, transient rash). Hypersensitivity reactions, including anaphylaxis, have been rarely reported and are typically attributable to cobalt or to excipients (benzyl alcohol in multi-dose vials) rather than to the cobalamin molecule itself 275.
Hypokalemia has been reported during the rapid hematological response to B12 repletion in patients with severe megaloblastic anemia (potassium is consumed during rapid erythropoiesis); serum potassium should be monitored in patients with severe anemia or in those with pre-existing electrolyte disturbance during the first week of therapy 2716. Rare reports of thrombosis during repletion of severe megaloblastic anemia are reported in the older literature 26.
The cyano moiety of cyanocobalamin is released during intracellular processing in trace amounts, historically of theoretical concern in patients with Leber's hereditary optic neuropathy and in heavy smokers with tobacco amblyopia (hydroxocobalamin is preferred in these specific contexts because it does not contribute cyanide and indeed scavenges it). For the great majority of patients without these conditions, the cyanide released from a 1000 mcg therapeutic dose is biologically negligible 2116.
There is no established upper intake level for vitamin B12; the Institute of Medicine did not set a tolerable upper intake limit because no toxic effect has been demonstrated at high doses. Oral cyanocobalamin 1000, 2000 mcg daily has been administered chronically in clinical trials without dose-limiting toxicity 1022.
Contraindications
Cyanocobalamin is contraindicated in patients with known hypersensitivity to cobalt or to any component of the formulation (including benzyl alcohol in multi-dose preservative-containing vials) 27. Cyanocobalamin is relatively contraindicated in Leber's hereditary optic neuropathy and in suspected tobacco amblyopia; hydroxocobalamin is preferred in these contexts because cyanocobalamin contributes trace cyanide that may exacerbate optic neuropathy.
Caution is warranted in patients with hypokalemia or polycythemia vera at the start of therapy because of potassium consumption during rapid erythropoiesis 27.
Drug interactions
Drugs that reduce B12 absorption over months to years include long-term metformin (dose-dependent, established in DPPOS) 20, long-term proton pump inhibitors and H2 receptor antagonists (which reduce gastric acid needed to release B12 from food protein), aminosalicylic acid, neomycin, colchicine, and chloramphenicol (which can blunt the hematological response to B12 repletion). The clinical implication is periodic biochemical screening in patients on long-term metformin or acid-suppressive therapy, with oral cyanocobalamin supplementation when biochemical deficiency develops 27.
Cyanocobalamin is not metabolized by cytochrome P450 enzymes and does not participate in CYP-mediated drug-drug interactions 27. Folic acid supplementation in the presence of unrecognized B12 deficiency can correct the megaloblastic anemia while neurological deficits progress, the historical reason to confirm B12 status before treating macrocytic anemia with folate alone 1621.
Adverse events
Reported adverse events with cyanocobalamin injection are uncommon and generally mild: injection-site pain, pruritus, transient rash, mild diarrhea, and headache. Anaphylaxis has been reported rarely; the cobalt ion and benzyl alcohol preservative (when present) are the typical culprits rather than the cobalamin molecule 27. Hypokalemia during the rapid hematological response in severe megaloblastic anemia is well documented and managed by monitoring and replacement 2716.
Adverse events with Nascobal intranasal spray are predominantly local: rhinitis, sneezing, and headache 28. Adverse events with oral cyanocobalamin are rare; in the Kuzminski 1998, Bolaman 2003, and Lacombe 2024 trials, oral 1000, 2000 mcg daily was well tolerated with no dose-limiting toxicity over the study durations 5726.
Monitoring
Monitoring Cyanocobalamin Therapy
Baseline evaluation includes serum B12, complete blood count with mean corpuscular volume, reticulocyte count, and consideration of methylmalonic acid and total plasma homocysteine when serum B12 is borderline (200, 350 pg/mL) or when neurological symptoms are present without anemia 6316. In suspected pernicious anemia, anti-intrinsic-factor antibodies (highly specific) and anti-parietal-cell antibodies (more sensitive but less specific) help establish the etiology 1821.
On therapy: reticulocyte response peaks at approximately one week; serum B12 rises rapidly with parenteral therapy. Methylmalonic acid and homocysteine normalize within days to weeks of effective repletion regardless of route 63. Hematological normalization (Hb, MCV) typically completes by 6, 8 weeks. Neurological response is variable and may continue improving over 6, 12 months; incomplete recovery is associated with longer pre-treatment duration of deficit 121. Serum potassium should be monitored during the first week of treatment in patients with severe megaloblastic anemia 27.
Special populations
Cyanocobalamin in Special Populations
Pregnancy
Vitamin B12 requirements increase modestly in pregnancy and lactation; the Recommended Dietary Allowance in pregnancy is 2.6 mcg/day. Cyanocobalamin is generally considered safe in pregnancy at usual replacement doses; untreated maternal B12 deficiency is associated with neural tube defects, intrauterine growth restriction, and infant neurological complications 27. Vegan and vegetarian pregnant patients are at particular risk and benefit from routine biochemical screening and supplementation 1721.
Lactation
Vitamin B12 is excreted in breast milk in proportion to maternal status. Cyanocobalamin supplementation in vegan or otherwise B12-insufficient lactating mothers is well established and protective against infant deficiency. Maternal supplementation is preferred to direct infant supplementation in most contexts 1721.
Pediatric
Infants born to vegan or B12-deficient mothers are at risk of severe neurodevelopmental consequences from cobalamin deficiency in the first year of life. Pediatric cyanocobalamin doses are weight-adjusted; the FDA-labeled pediatric IM dose is 100 mcg total over two or more weeks for nutritional deficiency, with higher doses in infants with congenital pernicious anemia or inborn errors of cobalamin metabolism 2721.
Geriatric
Older adults are the population at highest baseline risk for B12 deficiency, primarily because of food-cobalamin malabsorption from atrophic gastritis and from long-term acid-suppressive medication or metformin use 2294. Crystalline (free) cyanocobalamin in tablets or injections is absorbed normally in food-cobalamin malabsorption because it does not require gastric proteolytic release 2320. Oral cyanocobalamin 1000, 2000 mcg daily is the preferred initial therapy in many older adults with food-cobalamin malabsorption 24510.
Renal impairment
No dose adjustment is required in renal impairment. Renal handling of cyanocobalamin is minor at therapeutic doses 27. Serum methylmalonic acid is artifactually elevated in chronic kidney disease and should be interpreted with caution as a B12 status marker in patients with reduced eGFR 616.
Hepatic impairment
No dose adjustment is required in hepatic impairment. The hepatic store of cobalamin (1, 5 mg in healthy adults) is preserved across the range of usual hepatic dysfunction 2721.
Evidence quality
Cyanocobalamin Evidence Quality
The evidence base for cyanocobalamin is mature and consistent. The biochemistry of cobalamin-dependent enzymes is well characterized 2514. The clinical spectrum of vitamin B12 deficiency and the biochemical diagnostic markers (serum B12, methylmalonic acid, homocysteine) are codified across decades of work by Lindenbaum, Stabler, Allen, Savage, Snow, and others 42317. Epidemiology of deficiency in elderly adults, in vegetarians and vegans, and in patients on long-term metformin is well established 9201. The Nature Reviews Disease Primers monograph 21 and the NEJM Clinical Practice review 16 consolidate this evidence 2116.
Randomized comparative effectiveness data are unusually strong for a generic vitamin 626. The Kuzminski 1998 randomized comparison of oral 2000 mcg vs IM 1000 mcg cyanocobalamin and the Bolaman 2003 prospective randomized trial in megaloblastic anemia established equivalence of the two routes 5724. The Vidal-Alaball 2005 Cochrane systematic review and the updated Wang 2018 Cochrane review pooled randomized evidence and reaffirmed the equivalence conclusion 1022. Practice guidelines from the British Committee for Standards in Haematology 18 and contemporary reviews 19 translate the evidence into clinical recommendations 2. The VITACOG randomized trial 15 is the leading evidence base for the homocysteine-lowering hypothesis in cognitive decline 153.
Evidence specifically supporting compounded cyanocobalamin preparations is essentially absent, there is no separate efficacy program for compounded formulations because the manufactured FDA-approved cyanocobalamin injection is the reference product and is the basis for the pharmacology established above 20. Compounded use is therefore an individualization-driven extrapolation from the manufactured-product evidence, justified case-by-case by documented patient-specific clinical factors that the manufactured product cannot accommodate.
Case series of 141 consecutive patients with neuropsychiatric disorders caused by cobalamin deficiency
141
—
28% of patients with neuropsychiatric manifestations of cobalamin deficiency had neither anemia nor macrocytosis at presentation, undermining reliance on the CBC as a screening tool 1
Review and case series characterizing the clinical and biochemical spectrum of cobalamin deficiency
—
—
Established serum methylmalonic acid and total plasma homocysteine as functional biochemical markers of cobalamin status, more sensitive than serum cobalamin alone 2
Prospective comparison of serum methylmalonic acid and total homocysteine to serum cobalamin and folate in patients with biochemically confirmed cobalamin or folate deficiency
434
—
Methylmalonic acid elevated in 98% of cobalamin-deficient and total homocysteine in 96%; either marker more sensitive than serum cobalamin alone for diagnosis 3
Randomized, open-label, parallel-group comparison of oral cyanocobalamin 2000 mcg daily vs IM cyanocobalamin 1000 mcg on the standard induction-then-maintenance schedule in adults with newly diagnosed cobalamin deficiency
38
120 days
Equivalent normalization of serum cobalamin, methylmalonic acid, and homocysteine on oral 2000 mcg daily compared with IM 1000 mcg on the standard schedule; numerically higher serum cobalamin in the oral arm 5
Narrative review of laboratory tests for vitamin B12 and folate deficiency
—
—
Serum B12 has limited sensitivity; methylmalonic acid and total homocysteine provide functional confirmation; the practical diagnostic algorithm for primary care 6
Review of B12 deficiency epidemiology, etiology, and treatment in elderly adults
—
—
Food-cobalamin malabsorption is the dominant geriatric mechanism; crystalline cyanocobalamin (oral or parenteral) is absorbed normally because it does not require gastric proteolytic release from food protein 9
Randomized, double-blind, placebo-controlled trial of oral cyanocobalamin 1000 mcg with or without folic acid 400 mcg daily in older adults with mild B12 deficiency
195
24 weeks
Significant biochemical correction without a measurable effect on cognitive function endpoints at the trial duration 11
Systematic review of cobalamin deficiency prevalence in vegetarian and vegan populations across age groups
—
—
Prevalences of biochemical deficiency reached 62% in pregnant vegetarians and 86% in elderly vegans depending on diagnostic threshold; supplementation is universally indicated for vegans 17
British Committee for Standards in Haematology guideline for diagnosis and treatment of cobalamin and folate disorders
—
—
Practical evidence-based recommendations for screening, diagnosis (including thresholds for methylmalonic acid and homocysteine), and treatment routes 18
Post-hoc analysis of the Diabetes Prevention Program Outcomes Study examining long-term metformin exposure and biochemical B12 status
2155
Median 13 years follow-up
Dose-dependent association between cumulative metformin exposure and biochemical B12 deficiency; risk of low B12 approximately doubled in long-term metformin users vs placebo 20
Heterogeneity of clinical presentations and limited sensitivity of serum cobalamin as a single screening marker; argues for liberal use of MMA and homocysteine confirmation 23
State-of-the-art review of oral and intranasal cyanocobalamin therapy in older adults
—
—
Oral cyanocobalamin 1000 mcg daily is appropriate first-line therapy for B12 deficiency from food-cobalamin malabsorption in older adults; intranasal cyanocobalamin (Nascobal) is an alternative for maintenance 24
Review of MMACHC-mediated intracellular processing of cobalamins
—
—
MMACHC removes the upper axial ligand of incoming cobalamins (including the cyano group of cyanocobalamin) to generate a common cob(II)alamin intermediate that is then channeled into methylcobalamin and adenosylcobalamin 25
Prospective cohort study of oral cyanocobalamin in patients with pernicious anemia
—
—
Confirms effectiveness of high-dose oral cyanocobalamin in pernicious anemia in a contemporary clinical cohort; supports oral therapy as a reasonable first-line option in selected patients 26
Mechanism detail
Detailed Mechanism of Cyanocobalamin
Dietary vitamin B12 in animal foods is bound to proteins. Gastric acid and pepsin release B12 from food protein, after which it binds haptocorrin (R-binder) in saliva and gastric juice. In the duodenum, pancreatic proteases degrade haptocorrin and free B12 is transferred to intrinsic factor, a glycoprotein secreted by gastric parietal cells. The intrinsic factor-B12 complex traverses the small bowel and binds the cubilin-amnionless receptor (the cubam receptor) on enterocytes of the distal ileum, where it is internalized by receptor-mediated endocytosis 1421. Loss of any of these steps, achlorhydria from atrophic gastritis or chronic proton pump inhibitor use, autoimmune destruction of parietal cells (pernicious anemia), pancreatic exocrine insufficiency, ileal disease or resection, produces malabsorption.
After enterocyte uptake, B12 is exported into the portal circulation bound to transcobalamin II (the active transport carrier; the holotranscobalamin fraction is the metabolically available pool). Transcobalamin-B12 binds the transcobalamin receptor on target cells and is internalized to the lysosome, where the carrier is degraded and free cobalamin enters the cytosol. The MMACHC gene product processes incoming cobalamins by removing the upper axial ligand, including the cyano group of cyanocobalamin, to generate a common cob(II)alamin intermediate 25. This intermediate is methylated by methionine synthase reductase (MTRR) to produce methylcobalamin or trafficked to the mitochondrion and adenosylated by MMADHC and MMAB to produce 5'-deoxyadenosylcobalamin 2514.
Approximately 1, 3% of an oral dose of cyanocobalamin is absorbed by passive diffusion across the intestinal mucosa, independent of intrinsic factor 522. This mass-action absorption pathway is the mechanistic basis for high-dose oral cobalamin therapy in patients with pernicious anemia, food-cobalamin malabsorption, or terminal ileum disease: at 1000, 2000 mcg oral daily, the passively absorbed fraction (10, 60 mcg) exceeds daily requirements (2.4 mcg in adults). The Kuzminski 1998 randomized comparison and the Bolaman 2003 prospective trial established the clinical effectiveness of this approach, and the Vidal-Alaball 2005 and Wang 2018 Cochrane systematic reviews confirmed equivalence of high-dose oral to intramuscular cyanocobalamin on hematological and biochemical endpoints 710.
Parenteral cyanocobalamin bypasses the absorption cascade entirely. After IM or deep SC injection, a substantial fraction is bound to plasma haptocorrin and to transcobalamin II; tissue uptake is rapid and the elimination half-life from plasma is short (hours), but cobalamin is sequestered in hepatic stores (1, 5 mg total body store in healthy adults, predominantly hepatic) that buffer total body status for years 2114. Renal handling is minor at therapeutic doses; very high parenteral doses produce dose-proportional urinary loss because the protein-binding pool saturates.
Cyanocobalamin is absorbed by two parallel mechanisms after oral administration 27. The physiological pathway requires gastric acid and pepsin to release B12 from food protein, binding to haptocorrin in the stomach, transfer to intrinsic factor in the duodenum, and receptor-mediated uptake of the intrinsic factor-B12 complex by the cubilin-amnionless receptor in the distal ileum. Absorption by this pathway saturates at approximately 1.5, 2 mcg per meal and accounts for nutritional B12 intake. The non-physiological pathway is intrinsic-factor-independent passive diffusion across the intestinal mucosa, which absorbs approximately 1, 3% of an oral dose and is the basis for high-dose oral cyanocobalamin therapy 14215.
After absorption, cyanocobalamin is bound in plasma to transcobalamin II (active transport carrier, the holotranscobalamin pool) and haptocorrin. Tissue uptake is rapid; the plasma elimination half-life is short (hours) but the hepatic store (1, 5 mg in healthy adults) buffers total body status for years. Renal handling is minor at therapeutic doses; urinary loss becomes dose-proportional only at very high parenteral doses that saturate plasma protein binding. Cyanocobalamin itself is biologically inert until intracellular processing by MMACHC removes the cyano group; the resulting cob(II)alamin intermediate is methylated to methylcobalamin or adenosylated to 5'-deoxyadenosylcobalamin 251427.
Intramuscular and deep subcutaneous administration bypass the absorption cascade entirely; bioavailability is essentially complete. Intranasal cyanocobalamin (Nascobal) achieves bioavailability of approximately 7, 10% relative to intramuscular administration on a per-dose basis, supporting the 500 mcg weekly maintenance regimen 2827.
Pharmacodynamics
Pharmacodynamic effects of cyanocobalamin repletion in deficiency include rapid reticulocytosis (peaking at approximately one week), normalization of mean corpuscular volume over 6, 8 weeks, and biochemical normalization of methylmalonic acid and total homocysteine within days to weeks 1663. Neurological response is slower (weeks to months) and incomplete when treatment is delayed 112.
There is no pharmacodynamic indication for cyanocobalamin in adults with normal serum B12 and normal functional markers (methylmalonic acid, homocysteine); subjective effects on energy or mood in B12-replete adults are not supported by randomized placebo-controlled evidence.
Comparative formulations
Comparing Cyanocobalamin Formulations
The manufactured cyanocobalamin products are parenteral cyanocobalamin injection (1000 mcg/mL, IM or deep SC; FDA-approved generic) and Nascobal intranasal spray (500 mcg/0.1 mL, once weekly maintenance) 2728. Over-the-counter oral cyanocobalamin tablets are widely available at 100, 5000 mcg strengths. Among other B12 vitamers: hydroxocobalamin injection (preferred for cyanide-related conditions and for Leber's hereditary optic neuropathy) is available as a generic; methylcobalamin and adenosylcobalamin are available as oral supplements but are not FDA-approved as drugs.
Cyanocobalamin and hydroxocobalamin behave nearly identically in routine B12 repletion because both vitamers feed the same intracellular MMACHC processing step before becoming biologically active 2514. The empirical clinical choice between vitamers is driven by historical convention, specific contraindications (cyanocobalamin avoided in Leber's hereditary optic neuropathy; hydroxocobalamin preferred for cyanide poisoning), and availability rather than by demonstrable differences in routine repletion efficacy 27.
Compounded sterile injectable cyanocobalamin preparations differ from the manufactured 1000 mcg/mL generic primarily in concentration (e.g., 5 mg/mL or 10 mg/mL for IV-push protocols) and excipient profile (e.g., preservative-free formulations) 27. They are not bioequivalent to the manufactured product without separate stability and PK data.
Storage
Cyanocobalamin Storage and Handling
Manufactured cyanocobalamin injection is stored at controlled room temperature (20, 25°C; 68, 77°F) protected from light 31. Light exposure degrades cobalamins by photolysis; the product is supplied in amber glass and should be returned to the carton when not in use 27. Nascobal nasal spray is stored upright at controlled room temperature; use within the labeled in-use period after activation 28.
Compounded sterile cyanocobalamin preparations are stored per the pharmacy's stability data and beyond-use-date assignment under USP <797>. Light protection (amber containers, opaque overwraps, light-blocking storage cabinets) is a routine requirement. Refrigerated storage extends beyond-use dates relative to room temperature for many compounded sterile aqueous preparations 31.
RonanRx operations
Cyanocobalamin Compounding & Operations
503A compounding
Compounded cyanocobalamin is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares sterile injectable cyanocobalamin per USP General Chapter <797>, the official compendial standard for sterile pharmaceutical compounding, with documented active ingredient sourcing, gravimetric and analytical verification, sterility and endotoxin testing per the pharmacy's quality-management system, and full lot traceability 3130. Nonsterile preparative steps (when applicable) follow USP General Chapter <795> 32.
Compounded cyanocobalamin is dispensed only when the prescriber documents a patient-specific clinical need that the manufactured cyanocobalamin injection or Nascobal product cannot meet, consistent with FDA's section 503A guidance on compounded copies of commercially available drugs 29. Routine compounding of a 1000 mcg/mL cyanocobalamin injection identical to the manufactured generic is not appropriate and is not performed at RonanRx 3027.
Beyond-use dating, ingredient identity verification, sterility assurance, and stability assessment follow USP <797> requirements 30. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing.
Pharmacist review
Each prescription for compounded cyanocobalamin undergoes pharmacist review prior to dispensing 102218. The review confirms: a documented patient-specific clinical reason that the manufactured cyanocobalamin injection or Nascobal product is not appropriate (e.g., excipient sensitivity to benzyl alcohol or chlorobutanol; custom concentration for an IV-push protocol; a multi-vitamin injectable formula); absence of contraindications (cobalt hypersensitivity, Leber's hereditary optic neuropathy, tobacco amblyopia); appropriate biochemical evaluation of B12 status (serum B12, with reflex methylmalonic acid and homocysteine in borderline cases) where the prescription indication is treatment of suspected deficiency 6316; and a prescribed regimen consistent with the established clinical evidence on dose, route, and frequency 27.
RonanRx does not fill prescriptions for compounded cyanocobalamin that read as routine substitution of compounded for manufactured product without documented clinical rationale, consistent with FDA guidance on compounded copies of commercially available drugs 29275.
Quality and traceability
Cyanocobalamin active pharmaceutical ingredient is sourced from FDA-registered facilities with documented certificates of analysis (identity, purity, water content, residual solvents, microbial limits). Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, sterility test result (for sterile preparations), endotoxin test result, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.
Cold chain
Cyanocobalamin is not strictly a cold-chain product, the manufactured injection is stored at controlled room temperature with light protection 27. Compounded sterile aqueous cyanocobalamin preparations may be refrigerated to extend beyond-use dating relative to room-temperature storage, per the pharmacy's stability data 31. Light protection (amber containers, opaque overwraps) is a routine requirement throughout storage and transport because cobalamins are photolabile.
FAQ
Frequently Asked Questions About Cyanocobalamin
Is compounded cyanocobalamin the same as a generic B12 injection from the pharmacy?
No. FDA-approved cyanocobalamin injection (1000 mcg/mL) is a manufactured generic available at most pharmacies, inexpensive, and well established 27. Compounded cyanocobalamin is pharmacy-prepared on a patient-specific prescription and is appropriate only when the manufactured product cannot meet a documented clinical need, for example, a custom concentration for IV push, a preservative-free formulation, or a multi-vitamin injectable formula. Compounded drugs are not FDA-approved29.
When is compounded cyanocobalamin appropriate instead of the manufactured product?
When a documented patient-specific clinical need cannot be met by the manufactured 1000 mcg/mL injection or by Nascobal nasal spray, for example, a custom concentration (5 mg/mL or 10 mg/mL for IV-push protocols), a preservative-free formulation for benzyl alcohol or chlorobutanol sensitivity, a custom-strength sublingual troche, or a B-complex/methylation-cocktail injectable on a prescriber's individualized formula. Cost or convenience does not justify compounding under section 503A29.
Is oral B12 as good as B12 injections?
For most patients, yes. Two randomized trials (Kuzminski 1998 and Bolaman 2003) and two Cochrane systematic reviews (Vidal-Alaball 2005 and Wang 2018) showed that oral cyanocobalamin 1000, 2000 mcg daily produces equivalent biochemical and hematological correction to intramuscular cyanocobalamin 1000 mcg on the standard schedule, even in pernicious anemia 5710. Injections may still be preferred initially when there are severe neurological symptoms or when adherence cannot be assured 22.
Should everyone on metformin take a B12 supplement?
Long-term metformin use is associated with dose-dependent biochemical B12 deficiency (DPPOS, Aroda 2016) 20. Routine biochemical screening (serum B12, with reflex to methylmalonic acid or homocysteine in borderline cases) is reasonable in patients on metformin for several years, with oral cyanocobalamin supplementation when deficiency develops. Universal supplementation in all metformin users without screening is not formally recommended by current guidelines 18.
Do vegans need to supplement vitamin B12?
Yes. Plant foods contain no biologically meaningful B12; algae and fermented foods contain mostly inactive corrinoid analogs. Pawlak et al. (2014) found that biochemical B12 deficiency was highly prevalent across vegan and vegetarian populations (reaching 86% in elderly vegans) 17. Oral cyanocobalamin (1000 mcg daily or 2000 mcg weekly) is the standard intervention 13.
What are the most common side effects of cyanocobalamin injection?
Side effects are uncommon and generally mild: injection-site pain, transient rash, mild pruritus, and headache. Hypersensitivity reactions are rare and usually attributable to cobalt or to benzyl alcohol preservative in multi-dose vials. Hypokalemia is reported during the rapid hematological response in severe megaloblastic anemia and is managed by monitoring and replacement 2716.
Why is methylmalonic acid measured to diagnose B12 deficiency?
Serum B12 has limited sensitivity at borderline levels. Methylmalonic acid accumulates when the B12-dependent mitochondrial enzyme methylmalonyl-CoA mutase is functionally impaired; total plasma homocysteine accumulates when the B12-dependent cytosolic enzyme methionine synthase is functionally impaired 3. Both markers are more sensitive than serum B12 alone, are elevated in 96, 98% of biochemically confirmed deficiency cases (Savage 1994), and normalize within days to weeks of effective repletion 616.
Does RonanRx sell compounded cyanocobalamin directly to patients?
No. Compounded cyanocobalamin requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the manufactured cyanocobalamin injection or Nascobal product is not appropriate, plus pharmacist review before dispensing 29. RonanRx is not a direct-to-consumer storefront 30.
Clinician resource
Download the Cyanocobalamin Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[lindenbaum1988] Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, Marcell PD, Stabler SP, Allen RH. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. New England Journal of Medicine. 1988. PMID 3374544. (accessed 2026-05-11)
[stabler1990] Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990. PMID 2393714. (accessed 2026-05-11)
[savage1994] Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. American Journal of Medicine. 1994. PMID 8154512. (accessed 2026-05-11)
[stabler1997] Stabler SP. Vitamin B-12 deficiency in the elderly: current dilemmas. American Journal of Clinical Nutrition. 1997. PMID 9322547. (accessed 2026-05-11)
[kuzminski1998] Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998. PMID 9694707. (accessed 2026-05-11)
[snow1999] Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Archives of Internal Medicine. 1999. PMID 10386505. (accessed 2026-05-11)
[bolaman2003] Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clinical Therapeutics. 2003. PMID 14749150. (accessed 2026-05-11)
[stabler2004] Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. Annual Review of Nutrition. 2004. PMID 15189123. (accessed 2026-05-11)
[andres2004] Andrès E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, Noblet-Dick M, Maloisel F, Schlienger JL, Blicklé JF. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ : Canadian Medical Association Journal. 2004. PMID 15289425. (accessed 2026-05-11)
[vidalalaball2005] Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, McDowell I, Papaioannou A. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews. 2005. PMID 16034940. (accessed 2026-05-11)
[eussen2006] Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, Schneede J, Blom HJ, Hoefnagels WH, van Staveren WA. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. American Journal of Clinical Nutrition. 2006. PMID 16895884. (accessed 2026-05-11)
[reynolds2006] Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurology. 2006. PMID 17052662. (accessed 2026-05-11)
[watanabe2007] Watanabe F. Vitamin B12 sources and bioavailability. Experimental Biology and Medicine. 2007. PMID 17959839. (accessed 2026-05-11)
[quadros2010] Quadros EV. Advances in the understanding of cobalamin assimilation and metabolism. British Journal of Haematology. 2010. PMID 19832808. (accessed 2026-05-11)
[smith2010] Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010. PMID 20838622. (accessed 2026-05-11)
[stabler2013] Stabler SP. Clinical practice. Vitamin B12 deficiency. New England Journal of Medicine. 2013. PMID 23301732. (accessed 2026-05-11)
[pawlak2014] Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: a review of literature. European Journal of Clinical Nutrition. 2014. PMID 24667752. (accessed 2026-05-11)
[devalia2014] Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology. 2014. PMID 24942828. (accessed 2026-05-11)
[hunt2014] Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014. PMID 25189324. (accessed 2026-05-11)
[aroda2016] Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology and Metabolism. 2016. PMID 26900641. (accessed 2026-05-11)
[green2017] Green R, Allen LH, Bjørke-Monsen AL, Brito A, Guéant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, Ueland PM, Yajnik C. Vitamin B(12) deficiency. Nature Reviews Disease Primers. 2017. PMID 28660890. (accessed 2026-05-11)
[wang2018] Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B(12) versus intramuscular vitamin B(12) for vitamin B(12) deficiency. Cochrane Database of Systematic Reviews. 2018. PMID 29543316. (accessed 2026-05-11)
[wolffenbuttel2019] Wolffenbuttel BHR, Wouters HJCM, Heiner-Fokkema MR, van der Klauw MM. The Many Faces of Cobalamin (Vitamin B(12)) Deficiency. Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 2019. PMID 31193945. (accessed 2026-05-11)
[andres2020] Andrès E, Zulfiqar AA, Serraj K, Vogel T, Kaltenbach G. State of the art review: oral and nasal vitamin B12 therapy in the elderly. QJM : monthly journal of the Association of Physicians. 2020. PMID 30796433. (accessed 2026-05-11)
[hannibal2022] Hannibal L, Bolisetty K, Axhemi A, Mooney S, Yu A, Banerjee R, Padovani D. Intracellular processing of vitamin B(12) by MMACHC (CblC). Vitamins and Hormones. 2022. PMID 35337623. (accessed 2026-05-11)
[lacombe2024] Lacombe V, Lenaers AS, Urbanski G, Lacout C, Bigot P, Lavigne C, Ghali A. Oral vitamin B12 supplementation in pernicious anemia: a prospective cohort study. American Journal of Clinical Nutrition. 2024. PMID 38797248. (accessed 2026-05-11)
[fda_label_nascobal] U.S. Food and Drug Administration / National Library of Medicine DailyMed. Nascobal (cyanocobalamin) nasal spray — FDA Prescribing Information (DailyMed listing). DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=nascobal (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
How to access
How to Access Cyanocobalamin
Compounded Cyanocobalamin is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Cyanocobalamin, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Cyanocobalamin.
